Federal support for mRNA vaccine research appears in jeopardy after KFF Health News reported Sunday that officials at the ...

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report report published on Thursday ...

The most recent trading session ended with Moderna (MRNA) standing at $34.71, reflecting a +0.26% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.64%.

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

NIH officials also told a senior NIH-funded vaccine scientist in New York state, who does not conduct mRNA vaccine research ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.